Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from Pfizer

Drugmakers' low U.S. taxes belie their high sales

Most of the largest pharmaceutical companies report losing money in the United States, despite the majority of their sales coming from Americans. The result is lower U.S. taxes for the companies.

WEKU

Most at-risk Aussies don't have COVID-19 plan with a GP

Some 75 per cent of Australians at higher risk of serious illness from COVID-19 do not have a plan to manage the potentially-lethal virus, new research shows.

AAP

2 Defensive Stocks to Buy Now as 'Higher For Longer' Woes Rattle Markets

U.S. stocks fell yesterday as the 10-year Treasury yield rose above 4.5% amid sticky inflation. As markets turn volatile, Pfizer and Apple look like two defensive names worth considering.

Barchart

From analysis to the latest developments in health,
read the most diverse news in one place.

“WHERE ARE YOUR ETHICS?”: Lady Gaga Slammed For Promoting Migraine Med

"It's like you've become a complete[ly] different person," outraged fans said as they criticized Lady Gaga for the commercial for Pfizer's migraine medication. The post “WHERE ARE YOUR ETHICS?”: Lady Gaga Slammed For Promoting Migraine Med first appeared on Bored Panda.

Bored Panda

Down 32% in a Year, Should Investors Buy the Dip in Pfizer Stock?

Down more than 30% in a year, pharmaceutical company Pfizer trades near its 52-week lows. Is this the right time to buy in the dip?

Barchart

New mRNA therapy shows promise in treating 'ultrarare' inherited disease

Initial trial results suggest that a new mRNA therapy may be able to safely and effectively treat propionic acidemia, a rare metabolic disorder.

LiveScience

Manipal Hospitals collaborates with Pfizer to improve patient care

Manipal Hospitals partners with Pfizer to enhance adult vaccination program, focusing on preventing vaccine preventable diseases efficiently.

The Hindu

Read news from The Economist, FT, and more,
with one subscription

Cheaper private Covid jabs may end up as costly as pricier ones, say experts

Exclusive: Multi-dose vials could push up charge per patient, with experts warning cost could widen inequalities

The Guardian - UK

Cost of private Covid jabs risks widening health inequalities, experts warn

Concerns that some groups who are more at risk from virus face hefty price tag, as Boots set to charge almost £100 a shot

The Guardian - UK

Boots to offer Covid vaccines in England for nearly £100 a jab

Pharmacy to offer Pfizer/BioNTech vaccine to those not eligible for NHS booster shot from next week

The Guardian - UK

In a pandemic milestone, the NIH ends guidance on COVID treatment

The National Institutes of Health is sunsetting its influential COVID-19 treatment guidelines, used by millions of doctors to guide care during the pandemic.

WEKU

COVID patients can't get Paxlovid

The price is one reason Paxlovid is not reaching those who need it most

Salon

Why covid patients who could most benefit from paxlovid still aren’t getting it

During the pandemic, the federal government offered Americans a 5-day course of Paxlovid, the antiviral drug that lessens COVID-19 symptoms. But now that Pfizer is charging for it, confusion over insurance coverage, price, has made patients wary.

The Texas Tribune

Covid vaccines cut risk of virus-related heart failure and blood clots, study finds

Researchers say jabs substantially reduce for up to a year the chances of serious cardiovascular complications

The Guardian - UK

Get all your
news in one place.

100's of premium titles.
One news app.

Reason

Does Anonymity Defeat Associational Standing?

The Second Circuit divides over whether an association must identify an injured member by name for the purposes of Article III. (Updated)

Salon

U.S. must stop syphilis killing babies

The government isn’t doing much to prevent shortages of the only drug that treats syphilis during pregnancy

Barchart

Should You Buy These 2 Dividend Stocks Yielding More Than 5% Right Now?

There are other reasons to consider buying a dividend stock besides the high yield. Here's a closer look at two stocks that offer yields over 5% right now.

Barchart

2 Cheap Dividend Stocks to Buy This March and Hold for the Long Term

While the S&P 500 Index's dividend yield is just about half of its long-term averages, Ford and Pfizer are two dividend-paying stocks that offer healthy yields. Plus, their cheap valuations mean that there is a reasonable probability of upside over the next couple of years.

Get all your
news in one place.

100's of premium titles.
One news app.

International Business Times

50 Top Companies By Market Capitalization: The Global Giants

These companies are the ones that dominate the market and will continue to do so should factors remain constant.

WEKU

Surge in syphilis cases drives some doctors to ration penicillin

The drug is the go-to treatment for syphilis and the only one recommended for pregnant people. But a shortage of the injectable drug has prompted some public health agencies to ration it.

International Business Times

A Better Way To Fight Future Pandemics

Four years after the emergence of Covid-19, the conversation in global public health has moved on from dealing with an immediate crisis to how we can best prepare for the next pandemic.

Salon

Large COVID-19 vaccine study finds risks

Any pharmaceutical has risk of side effects, but a COVID infection is far more dangerous than the vaccines

The Guardian - AU

Two very rare Covid vaccine side-effects detected in global study of 99 million

Results confirm how uncommon known complications are as researchers confirm benefits from vaccines still ‘vastly outweigh the risks’

StockNews.com

Pfizer (PFE) vs. Johnson & Johnson (JNJ) - Analyzing Pharma Stocks for Upside Potential

The pharmaceutical industry is expected to witness robust growth over the coming years due to growing healthcare needs and advancements in technology. Given this positive backdrop, let’s analyze the upside potential of pharma stocks Pfizer (PFE) and Johnson & Johnson (JNJ).

Barchart

Pfizer Stock 2025 Forecast: Will PFE Go Up Long Term?

Pfizer stock is trading at price levels last seen in 2016. The 2025 forecast for PFE stock looks positive, though, and it should go up over the medium to long term.

1 … 16 17 18 19

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.